Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series

Dayong Lee¹, Se Jeong Kim², Yeon Hee Hong², Seul Ki Kim¹, Byung Chul Jee¹
Department of Obstetrics and Gynecology, ¹Seoul National University Bundang Hospital, Seongnam, ²Seoul National University Hospital, Seoul, Korea

Objective
To report an efficacy of gonadotropin releasing hormone (GnRH) antagonist administration after freezing of all embryos for treatment of early type ovarian hyperstimulation syndrome (OHSS).

Methods
In 10 women who developed fulminant early type OHSS after freezing of all embryos, GnRH antagonist (cetrorelix 0.25 mg per day) was started at the time of hospitalization and continued for 2 to 4 days. Fluid therapy and drainage of ascites was performed as usual.

Results
Early type OHSS was successfully treated without any complication. At hospitalization, the median (95% confidence interval [CI]) of the right and the left ovarian diameter was 10.0 cm (7.6 to 12.9 cm) and 8.5 cm (7.5 to 12.6 cm). After completion of GnRH antagonist administration, it was decreased to 7.4 cm (6.2 to 10.7 cm) (P=0.028) and 7.8 cm (5.7 to 12.2 cm) (P=0.116), respectively. The median duration of hospital stay was 6 days (3 to 11 days). Trans-abdominal drainage of ascites was performed in 2 women and drainage of ascites by percutaneous indwelling catheter was performed in 4 women. No side effect of GnRH antagonist was noted.

Conclusion
GnRH antagonist administration appears to be safe and effective for women with fulminant early type OHSS after freezing all embryos. Optimal dose or duration of GnRH antagonist should be further determined.

Keywords: Ovarian hyperstimulation syndrome; Gonadotropin-releasing hormone; Antagonists & inhibitors; Cetrorelix
Several strategies for prevention of early type OHSS have been suggested; coasting or use of modified ovulation triggering method such as low-dose hCG, recombinant luteinizing hormone (LH), or gonadotropin releasing hormone (GnRH) agonist. At the time of ovum pick up, administration of aspirin, methylprednisolone, cabergoline, IV albumin, or IV calcium was also suggested. However, none of those cannot eliminate early type OHSS completely [1,4].

After ovum pick up, prolonged administration of GnRH agonist was suggested to prevent development of early type OHSS [5]. In a non-randomized controlled trial, Endo et al. [6] administered a GnRH agonist for 7 days after hCG triggering in women undergoing freezing of all embryos due to a high risk of OHSS. The incidence of severe OHSS was significantly lower in the group in which GnRH agonist was continued, compared with the group in which GnRH agonist was discontinued. Prolonged administration of GnRH agonist might suppress ovarian enlargement and associated hormonal factors. However, a 5-day course of GnRH antagonist from the day of ovum pick up did not reduce the incidence of early type severe OHSS [7].

In patients developing fulminant early type OHSS, there are no definitive therapeutic medications that effectively treat an established OHSS. Lainas et al. [8] first reported a successful treatment of severe early type OHSS with daily administration of 0.25 mg GnRH antagonist (garelix, Antagon™; Organon Inc., West Orange, NJ, USA) for 7 days in 3 women, combined with freezing of all embryos. Quick regression of the syndrome was achieved without hospitalization in all patients and no complications were reported. They showed that 1-week course of GnRH antagonist might lead to rapid pituitary dysfunction and ovarian regression.

In a subsequent study by same researchers, daily administration of 0.25 mg GnRH antagonist (garelix) for 4 days successfully treated severe early type OHSS in 3 women with polycystic ovary syndrome [9]. In a subsequent study, embryo transfer was attempted and 2 women became pregnant and delivered healthy baby [10].

In a recent prospective cohort study by same researchers, daily administration of 0.25 mg GnRH antagonist (garelix) for 4 days combined with freezing of all embryos successfully treated severe early type OHSS in 40 women. None of them required hospitalization and severe OHSS rapidly resolved in all women [11]. In a study by other researchers, a 2-day course of GnRH antagonist (cetrorex, Cetrotide®; Merck-Serono, Darmstadt, Germany) was also sufficient for treatment of early type OHSS [12].

From the above reports, we have administered GnRH antagonist (cetrorexil) in women developed severe early type OHSS after freezing-all-embryo since 2014. Here we report our treatment outcomes.

Materials and methods

1. Subjects
A retrospective analysis was performed after approval by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-1702-384-109). We administered GnRH antagonist (cetrorexil) in 10 hospitalized women for the treatment of severe early type OHSS admitted during November 2014 and July 2016. In 3 patients, oocyte retrieval was performed in our hospital, and in 7 patients, oocyte retrieval was performed in other clinics. Severe early type OHSS were developed 3–6 days after ovulation triggering (median, 3 days). All oocytes or embryos were frozen in all patients.

In 7 patients, GnRH antagonist protocol was used during ovarian stimulation, and GnRH agonist protocol was used during ovarian stimulation in 3 patients. In 6 patients, ovulation was triggered by recombinant hCG; dual triggering was used in 3 patients, and GnRH agonist triggering was used in 1 patient. Detailed ovarian stimulation outcomes in 10 patients were presented in Table 1. Before admission, no women received preventive measures except freezing all oocytes and embryos.

Table 1. Ovarian stimulation outcomes in 10 patients

| Variables                        | Values               |
|----------------------------------|----------------------|
| Age of women (yr)                | 33.5 (31.0–37.0)     |
| Body mass index (kg/m²)          | 21.3 (18.0–22.5)     |
| Baseline serum LH (IU/L)         | 5.8 (0.1–13.5)       |
| Baseline serum FSH (IU/L)        | 5.6 (3.4–8.5)        |
| Baseline AMH (ng/mL)             | 13.7 (4.0–22.0)      |
| Total exogenous FSH dose (IU)    | 2,062 (1,575–2,700)  |
| Serum estradiol at triggering day (pg/mL) | 1,560 (455–11,147)  |
| Serum progesterone at triggering day (ng/mL) | 1.7 (0.5–4.2)      |
| No. of total oocytes             | 28.5 (19–46)         |
| No. of mature oocytes            | 25.5 (12–40)         |

Values are presented as median (95% CI).

LH, luteinizing hormone; FSH, follicle stimulating hormone; AMH, anti-Mullerian hormone; CI, confidence interval.
Dayong Lee, et al. GnRH antagonist for treatment of OHSS

At admission, all women met the following criteria for severe early type OHSS; 1) presence of abdominal distension and/or dyspnea, 2) maximum diameter of ovary >7 cm, and 3) presence of ascites (depth of pocket >2 cm).

2. Management
Based on previous studies, GnRH antagonist (cetrorelix 0.25 mg per day) administration was planned for 4 days starting at the time of hospitalization, but the duration could be modified according to clinician’s decision referenced by improvement of the patients’ symptoms and signs [10,11]. We informed all women about the off-label use of GnRH antagonist, and GnRH antagonist was used only in patients who consented to the use. The duration of administration was determined according to the improvement of the patient’s symptoms and signs.

Conservative treatments such as fluid supplementation, drainage of ascites, and use of anticoagulant (enoxaparin 20 or 40 mg per day, Clexane®; Sanofi-Aventis, Paris, France) were performed as usual. Percutaneous indwelling catheter was inserted if patients were thought to be in need of frequent ascites drainage.

Vital signs and body weight was recorded daily. Blood tests including white cell count and hematocrit and trans-vaginal or trans-abdominal ultrasonography were performed every 1–2 days according to the patient’s symptoms and signs.

Data are expressed as median (95% confidence interval [CI]). When the median value for clinical and laboratory parameters before and after GnRH antagonist was compared, the paired Wilcoxon signed rank test was used. A P-value of <0.05 was considered as statistical significance.

Results
Ovarian stimulation outcomes are described in Table 1. Two patients received 0.5 mg of GnRH antagonist for 1 day. GnRH antagonist 0.25 mg/day was used for 2 days in 3 patients, for 3 days in 4 patients, and for 4 days in 1 patient.

Several indices of body measurement, hematologic, laboratory, and ultrasonography before and after GnRH antagonist treatment and at the time of discharge are summarized in Table 2. Body weight, abdominal circumference, white blood cell (WBC) count, and hematocrits were decreased, and daily amount of urine output were increased during hospital course. The maximal diameters were significantly decreased in the right ovary but not in the left ovary.

In Fig. 1, maximal diameter of the right and the left ovary during hospital course are depicted in 6 patients. During hos-

---

**Table 2.** Serial changes of clinical and laboratory parameters during admission in 10 patients

| Variables                        | At admission          | At completion of GnRH antagonist | Before discharge |
|----------------------------------|-----------------------|----------------------------------|------------------|
| Body weight (kg)                 | 57.3 (41.1–65.2)      | 59.2 (42.9–65.5)                 | 55.0 (41.1–62.1) |
| Abdominal circumference (cm)     | 85.0 (69.0–88.7)      | 83.1 (72.0–92.5)                 | 81.3 (70.0–90.5) |
| WBC count (/µL)                  | 15,950 (10,800–25,900)| 9,290 (3,100–13,600)            | 9,220 (3,100–12,100) |
| Hematocrit (%)                   | 46.1 (42.9–50.9)      | 34.6 (27.0–38.5)                | 35.4 (30.2–38.5) |
| AST (IU/L)                       | 32 (14–70)            | 25 (17–57)                      | -                |
| ALT (IU/L)                       | 17 (6–51)             | 17 (7–51)                       | -                |
| Maximal diameter of the right ovary (cm) | 10.0 (7.6–12.9)       | 7.4 (6.2–10.7)                  | -                |
| Maximal diameter of the left ovary (cm) | 8.5 (7.5–12.6)        | 7.8 (5.7–12.2)                  | -                |
| Total amount of ascites drained (mL) | -                     | -                                | 6,250 (3,605–13,753) |
| Daily amount of urine output (mL) | 1,495 (550–3,010)     | 2,250 (320–5,050)               | 3,510 (320–4,950) |

Values are presented as median (95% CI). GnRH, gonadotropin releasing hormone; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine transaminase; CI, confidence interval.

*Significant when compared with the value at admission (Wilcoxon signed rank test); †Diameter of ovary at completion of GnRH antagonist was measured in 6 patients; ‡Drainage of ascites was not performed in 4 patients; ‡‡24 hours urine output on the next day after admission.
pitalization, trans-abdominal drainage of ascites by 18G needle was performed in 2 women (2 times for each). Drainage of ascites by percutaneous indwelling catheter was performed in 4 women. The median duration of indwelling catheter was 6 days (range, 2 to 11 days). Seven patients received daily anticoagulant.

In all patients, OHSS was successfully treated without any complication. The median duration of hospital stay was 6.6 days (range, 3 to 11 days). No side effect of GnRH antagonist was noted.

**Discussion**

In all patients, symptoms and clinical and laboratory indices were improved after GnRH antagonist administration. The median duration of hospital stay was 6 days (range, 3 to 11 days). Two out of 10 patients were hospitalized for more than 8 days. One patient received GnRH antagonist 3 times from the time of admission and overall symptoms were improved, however, cardiopulmonary symptoms such as bilateral leg edema, bilateral pleural effusion, and tachycardia persisted; this patient was discharged on the 10th day after cardiopulmonary work up. Another patient underwent IVF for oocyte freezing before chemotherapy for breast cancer; overall symptoms were improved after 2 doses of GnRH antagonist, but this patient was discharged on the 11th day because of management of neutropenia occurred after chemotherapy.

If hypovolemia and hemoconcentration are not corrected properly, prerenal insufficiency would be developed, which leads to oliguria and elevation of blood urea nitrogen (BUN) and creatinine [13]. When hypovolemia is corrected, the urine volume increases [14]. In our study, daily urine volume increased from 1,495 to 2,250 mL during GnRH antagonist treatment and it further increased to 3,510 mL at the time of discharge. Our result was similar to previous study, in which the daily urine volume increased from 1,889 to 2,660 mL after paracentesis of ascites [15].

In our series, both ovarian sizes were decreased during GnRH antagonist treatment. There was a statistically significant decrease in the diameter of the right ovary after treatment, but not in the diameter of the left ovary. Interestingly, initial median diameter was much greater in the right ovary than the left ovary (10.0 vs. 8.5 cm). This phenomenon might
be associated with the findings that more oocytes were obtained in the right ovary after controlled ovarian stimulation [16,17]. The frequency of ovulation in the right ovary was significantly higher than in the left ovary when comparing the frequency of ovulation in both fertile and infertile women (55% vs. 45%; P<0.05) [18]. The mechanism of an asynchrony in the activity of both ovaries is not yet clear but changes of inter-ovarian control mechanisms upon aging, and differences in innervation, vascular distributions, or anatomic asymmetry were suggested to explain the different response to ovarian hyperstimulation [16,18-20].

The role of the GnRH antagonist on the pituitary gland is primarily to decrease the secretion of endogenous LH. However, even in patients with OHSS, serum LH level in the luteal phase is low. Thus, direct ovarian action of GnRH antagonist has been suggested. GnRH receptors have been reported to be present in granulosa-lutein cells [21,22]. Previous studies have shown that mRNA and protein expression for vascular endothelial growth factor (VEGF) and VEGF receptor are reduced in cultured human granulosa-lutein cell under GnRH antagonist administration [23,24]. In a rat model, the GnRH antagonist administration reduced mRNA expression for VEGF and VEGF receptor in the hyperstimulated ovaries [24]. The use of GnRH antagonist in the luteal phase for rapid luteolysis has been reported in patients requiring rapid ovulation induction for cancer treatment [25]. In this case report, authors reported that rapid progesterone reduction after GnRH antagonist administration was observed and menstruation started 2–4 days later. In a previous study comparing functional changes and ultrastructural characteristics of natural luteolysis and GnRH antagonist induced luteolysis, luteolysis through GnRH antagonist treatment has been identified as involving proteins or cells different from naturally occurring luteolysis [26]. Thus, it is considered that the 2 processes occur with different mechanisms. Considering these results, GnRH antagonist administration may have different mechanisms than natural luteolysis and rapidly reduce the various vasoactive cytokines including VEGF produced by corpus luteum preventing the progression of OHSS.

Our study was a retrospective case series; therefore, there was no control group. In addition, small number of patients was included. Thus, prospective controlled studies with more patients will be needed in the future.

In conclusion, freezing of all embryos and GnRH antagonist administration appears to be safe and effective for women fulminant OHSS. Dose of GnRH antagonist and duration of its use should be further investigated.

**Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

**References**

1. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2016;106:1634-47.
2. D’Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002;17:2787-94.
3. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901-7.
4. Farquhar C, Marjoribanks J, Brown J, Fauser BC, Lethaby A, Mourad S, et al. Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance. Reprod Biomed Online 2017;35:3-16.
5. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod 1992;7:320-7.
6. Endo T, Honnma H, Hayashi T, Chida M, Yamazaki K, Kitajima Y, et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod 2002;17:2548-51.
7. Wang YQ, Yu N, Xu WM, Xie QZ, Yan WJ, Wu GX, et al. Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: a controlled clinical study. Exp Ther Med 2014;8:1855-60.
8. Lainas TG, Sfountouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007;15:408-12.
9. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Iliadis GS, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online 2009;18:15-20.

10. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, et al. Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase. Reprod Biomed Online 2009;19:789-95.

11. Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Tarlatzi TB, et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol 2012;10:69.

12. Hosseini MA, Mahdavi A, Aleyasin A, Safdarian L, Bahmaee F. Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study. Gynecol Endocrinol 2012;28:853-5.

13. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003;9:77-96.

14. Schenker JG. Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993;8:653-9.

15. Levin I, Almog B, Avni A, Baram A, Lessing JB, Gamzu R. Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome. Fertil Steril 2002;77:986-8.

16. Lan KC, Huang FJ, Lin YC, Kung FT, Lan TH, Chang SY. Significantly superior response in the right ovary compared with the left ovary after stimulation with follicle-stimulating hormone in a pituitary down-regulation regimen. Fertil Steril 2010;93:2269-73.

17. Choe SA, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM, et al. Symmetry in number of retrieved oocytes between two ovaries: a possible predictor of in vitro fertilization outcome. Gynecol Endocrinol 2011;27:997-1000.

18. Fukuda M, Fukuda K, Andersen CY, Byskov AG. Characteristics of human ovulation in natural cycles correlated with age and achievement of pregnancy. Hum Reprod 2001;16:2501-7.

19. Potashnik G, Insler V, Meizner I, Sternberg M. Frequency, sequence, and side of ovulation in women menstruating normally. Br Med J (Clin Res Ed) 1987;294:219.

20. Dominguez R, Cruz ME, Chavez R. Differences in the ovulatory ability between the right and left ovary are related to ovarian innervation. In: Hirshfield AN, editor. Growth factors and the ovary. Boston (MA): Springer; 1989. p.321-5.

21. Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L, et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 1989;125:1739-41.

22. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 1995;80:430-4.

23. Asimakopoulos B, Nikolettos N, Nehls B, Diedrich K, Al-Hasani S, Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril 2006;86:636-41.

24. Taylor PD, Hillier SG, Fraser HM. Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J Endocrinol 2004;183:1-17.

25. Fridén BE, Nilsson L. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta Obstet Gynecol Scand 2005;84:812-6.

26. Del Canto F, Sierralta W, Kohen P, Muñoz A, Strauss JF 3rd, Devoto L. Features of natural and gonadotropin-releasing hormone antagonist-induced corpus luteum regression and effects of in vivo human chorionic gonadotropin. J Clin Endocrinol Metab 2007;92:4436-43.